Hirata T, Ogawa E, Takenaka K, Kawashita F
Department of Thoracic Surgery, Kishiwada City Hospital, Kishiwada, Osaka, Japan.
Eur Surg Res. 2004 Jan-Feb;36(1):13-9. doi: 10.1159/000075069.
We examined whether clarithromycin (CAM), a 14-membered macrolide, can control the postoperative systemic inflammatory response syndrome that occurs following lung cancer surgery. In the control group (n = 16), prophylactic antibiotics (flomoxef) were administered for 4-7 days following surgery. In the CAM group (n = 10), 400 mg/day of CAM were administered orally for 14 days prior to surgery and for 7 days following surgery, in addition to the postoperative administration of flomoxef. The incidence and duration of the systemic inflammatory response syndrome in the CAM group (30%, 0.3 days) were significantly lower than those in the control group (81%, 1.6 days). There were no significant differences between the control and CAM groups in both the amount and frequency of nonsteroidal anti-inflammatory drugs following surgery. In conclusion, our study suggests that CAM may suppress the postoperative systemic inflammatory response syndrome in lung cancer patients.
我们研究了14元大环内酯类药物克拉霉素（CAM）是否能够控制肺癌手术后发生的全身炎症反应综合征。在对照组（n = 16）中，术后给予预防性抗生素（氟氧头孢）4 - 7天。在CAM组（n = 10）中，除术后给予氟氧头孢外，术前14天及术后7天每天口服400 mg CAM。CAM组全身炎症反应综合征的发生率（30%）和持续时间（0.3天）显著低于对照组（81%，1.6天）。术后两组在非甾体抗炎药的用量和使用频率方面均无显著差异。总之，我们的研究表明CAM可能会抑制肺癌患者术后的全身炎症反应综合征。
